Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1053/jlts.2002.29762 | DOI Listing |
Oncologist
January 2025
Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
Immune checkpoint inhibitors (ICIs) have advanced the treatment of metastatic melanoma. However, some patients develop ICI-associated toxicities like hepatitis (ie, immune-mediated hepatitis; IMH). Although these toxicities usually resolve with steroids, steroid-refractory events may occur, which may be a major source of morbidity and mortality without obviously defined treatment algorithms.
View Article and Find Full Text PDFRheumatology (Oxford)
January 2025
Department of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, India.
Objectives: To describe the clinical profile and compare the long-term outcomes of patients with S-PAN treated with various treatment regimens at our centre in the last 2 decades.
Methods: Data regarding clinical presentation, treatment allocation, relapses and outcomes of patients fulfilling American College of Rheumatology (ACR) 1990 criteria for PAN in the last 2 decades were recorded from electronic medical records. Relapse-free survival and predictors were analysed using KM survival statistics and regression analysis.
Rev Med Chil
June 2024
Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Liver transplantation (LT) is a cost-effective therapy for advanced liver disease. Although LT significantly improves long-term survival, it requires strict control of immunosuppressants and their potential complications. Several available immunosuppressive drugs include glucocorticoids, calcineurin inhibitors, mycophenolate, mTOR inhibitors, and anti-CD25 antibodies.
View Article and Find Full Text PDFAm J Transplant
December 2024
Division for Paediatric Gastroenterology and Hepatology, Department of Paediatric Kidney, Liver, and Metabolic Diseases, Hannover Medical School, Hannover, Germany.
This retrospective study aimed to investigate the response to hepatitis A virus (HAV) immunization following liver transplantation. We analyzed 234 vaccination records of 284 children who underwent liver transplantation between January 2003 and July 2021, including annual serologic results. Of the 120 HAV-naïve patients, approximately 71% and 83% showed seroconversion after receiving 1 and 2 vaccine doses, respectively.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!